An observational study in HELICOBACTER PYLORI INFECTIONS, sponsored by Poitiers University Hospital. Recruiting at 1 site in France. Open to participants aged Up to 16 Years. Per ClinicalTrials.gov, last updated 2025-11-20.
Sponsored by Poitiers University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Communicable Diseases with a site in France — 16 open to participants now, 16 under way, 2 of them phase 3. Communicable Diseases · France.
Among the 42 studies in Communicable Diseases with a site in France, this one is the 20th largest by planned enrollment of the 31 observational ones that give a count, is one of 3 that started in 2025, is one of 31 observational ones, reaches primary completion later than 7 of the 15 other live ones, and was the 36th registered.
628 studies on the registry are indexed under Communicable Diseases; 129 are open to participants now.
Browse Communicable Diseases studies →16 of the 42 studies in Communicable Diseases with a site in France are open now. Recruiting first, the newest first:
AusperBio Therapeutics Inc. · Sites in France, United States, Canada and 3 more countries
Ages 18–65
ANRS, Emerging Infectious Diseases · Sites in France
Ages 18+
University of Minnesota · Sites in France, United States, Argentina and 18 more countries
Ages 18+
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
Ages 18+ · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 91 Communicable Diseases studies recruiting now, 49 (54%) set no upper age limit and 32 (35%) stop at 75 or younger; 35 take children under 18; 40 take healthy volunteers.
This study: Up to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 188 is close to the median of 200 across 229 observational studies indexed under Communicable Diseases.
Median enrollment 75 across the 11 interventional studies, 334 across the 31 observational. Of the 22 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 42 have an industry lead sponsor. The 10 most frequent:
Poitiers University Hospital is the lead sponsor of 315 studies on the registry; 63 are open to participants now.
Poitiers University Hospital has 1 study filed under Communicable Diseases — fewer than ten, so there is no comparison to draw.
7 of the studies in Communicable Diseases with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05903352Phase 3Assistance Publique - Hôpitaux de ParisCustomized Antibiotic Treatment Duration Among Hospitalized Patients With Moderately Severe Community-Acquired Pneumonia | 2027-05 |
| NCT05814237European Clinical Research Alliance for Infectious Diseases (ECRAID)POS-ARI-ER Observational Study of Acute Respiratory Infections | 2027-02-28 |
| NCT06893757ANRS, Emerging Infectious DiseasesProspective Cohort of People Starting Treatment for Tuberculosis Disease in France (FrenchTB) | 2027-06 |
| NCT06024421Institut National de la Santé Et de la Recherche Médicale, FranceEvaluation of Tolerance and Pharmacokinetic Profile of High Doses of Favipiravir in Healthy Volunteers | 2027-06 |
| NCT07069400University of MinnesotaAn International Observational Study of Adults With Acute Infection | 2027-06-08 |
Add all 7 to your calendar (.ics) → With an account.
Among the 42 studies in Communicable Diseases with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Helicobacter pylori infection is a widespread bacterial disease affecting nearly half of the world's population. In children, the infection displays distinct features versus adults, with lower prevalence, variable symptoms, and differing endoscopic and histological appearances.
Typically acquired in early childhood, its transmission is closely linked to socio-economic disadvantage and overcrowding. Although most infected children are asymptomatic, some develop epigastric pain, dyspepsia, weight loss, or other gastrointestinal disturbances. Chronic infection may eventually lead to mucosal atrophy and intestinal metaplasia, increasing the risk of gastric cancer later in life. Given the limitations and risks of invasive diagnostic methods-especially endoscopy under general anesthesia-there is a critical need for reliable, non-invasive tests. Recent adult studies indicate that stool-based PCR is a promising alternative for both detecting H. pylori and identifying clarithromycin resistance.
The primary objectives of this study are to evaluate the intrinsic diagnostic performance of high-resolution melt PCR (HP PCR) in stools, and to compare these results with those obtained from a conventional work-up, such as gastric biopsies, in a paediatric population. In accordance with prevailing rationality, the principal outcome of this study will be an evaluation of the intrinsic diagnostic capabilities of the proposed method. This will be accomplished by conducting a comparison of the sensitivity and specificity of the PCR test in stools with those of gastric biopsies (reference test).
Children requiring gastric biopsies for H. pylori detection
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Non-inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pediatric patients consulted/hospitalized for sampling for the presence or absence of Helicobacter pylori.
Diagnostic Test: Gastric biopsies · Diagnostic Test: Stool sampling
After obtaining informed consent, patients receive routine endoscopic procedures with an additional biopsy taken for research purposes. Invasive screening method used in routine care.
Stool samples are taken and sent within 10 days of the endoscopy. Self-collected stool samples are analyzed using antigen testing and molecular techniques to detect H. pylori and associated resistance mutations. Experimental diagnosis.
Evaluate the diagnostic performance of H. pylori PCR in stools
Diagnostic capabilities will be assessed by the error rate (false positives and negatives) of the stool PCR test, compared with the results of PCR biopsy (reference test).
Time frame: 10 days
Evaluate the intrinsic diagnostic performance (Se, Sp) of H. pylori PCR in stools
Intrinsic diagnostic capabilities will be assessed by comparing the sensitivity and specificity of the stool PCR test with the results of gastric biopsies (reference test).
Time frame: 10 days
Evaluate the extrinsic diagnostic performance (PPV, NPV) of H. pylori PCR in stools
Extrinsic diagnostic capabilities will be assessed by comparing the positive and negative predictive values of the stool PCR test with the results of gastric biopsies (reference test).
Time frame: 10 days
Evaluate the intrinsic diagnostic performance (Se, Sp) of clarithromycin-resistant H. pylori PCR in stools
Intrinsic diagnostic capabilities will be assessed by comparing the sensitivity, specificity and positive and negative predictive values of the clarithromycin-resistant H. pylori PCR test in stools with those of gastric biopsies (reference test).
Time frame: 10 days
Evaluate the extrinsic diagnostic performance (PPV, NPV) of clarithromycin-resistant H. pylori PCR in stools
Extrinsic diagnostic capabilities will be assessed by comparing the sensitivity and specificity, as well as the positive and negative predictive values, of the clarithromycin-resistant H. pylori PCR test in stools with the results of gastric biopsies (reference test).
Time frame: 10 days
Evaluate the intrinsic and extrinsic diagnostic performance of H. pylori PCR and H. pylori antigen in stools
Intrinsic and extrinsic diagnostic capabilities will be assessed by comparing the sensitivity and specificity and positive and negative predictive values of the stool antigen test with the results of gastric biopsies (reference test).
Time frame: 10 days
Evaluate the intrinsic diagnostic performance (Se, Sp) of H. pylori PCR in stools
Intrinsic diagnostic capabilities will be assessed by the sensitivity and specificity and positive and negative predictive values of the stool PCR test, and compared with stool antigen results.
Time frame: 10 days
Evaluate the extrinsic diagnostic performance (PPV, NPV) of H. pylori PCR in stool
Extrinsic diagnostic capabilities will be assessed by the sensitivity and specificity and positive and negative predictive values of the stool PCR test, and compared with stool antigen results.
Time frame: 10 days
Evaluate the adherence of a stool self-sampling for H. pylori
Adherence to stool sampling will be assessed by the number of stool samples received in the population analyzed out of the number of patients included
Time frame: 10 days
Analyze resistance profiles to the various antibiotics used in Helicobacter pylori eradication therapy
Analyze resistance profiles to the various antibiotics used in Helicobacter pylori eradication therapy in relation to biological test results (PCR in biopsy and stool, stool antigens) and clinical presentation. Resistance profiles will be expressed in micrograms per mL and interpreted in accordance with the current guidelines of the Antibiogram Committee of the French Microbiology Society.
Time frame: 10 days
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Oct 2027, 24 months after the start.
Of 128 non-industry observational studies under Communicable Diseases, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 77. This study's planned 24 months is below that.
Counting every sponsor, half of 142 studies reached it within 37 months; a quarter within 17 and three quarters within 94.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Poitiers University Hospital →